REGN Q4 2022 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.4B-31.0% YoY

Gross Profit

$2.9B85.2% margin

Operating Income

$1.3B38.5% margin

Net Income

$1.2B35.1% margin

EPS (Diluted)

$10.50

QoQ Revenue Growth

+16.3%

Cash Flow

Operating Cash Flow

$1.7B

Free Cash Flow

$1.6B

Stock-Based Comp.

$232M

Balance Sheet

Total Assets

$29.2B

Total Liabilities

$6.6B

Stockholders' Equity

$22.7B

Cash & Equivalents

$3.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.4B	$5.0B	-31.0%
Gross Profit	$2.9B	$3.9B	-25.3%
Operating Income	$1.3B	$2.6B	-50.2%
Net Income	$1.2B	$2.2B	-46.3%

Revenue Segments

Product

$1.7B93%

Product and Service, Other

$128M7%